Meeting
2019 ASCO Annual Meeting
Lasofoxifene as a potential treatment for ER+ metastatic breast cancer.
Authors
Muriel Laine
University of Chicago, Chicago, IL
Muriel Laine , Sean William Fanning , Marianne Greene , Ya-fang Chang , Linda Phung , Tina T Tan , Richard Hiipakka , Barry Komm , Geoffrey Greene
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1056)
DOI
10.1200/JCO.2019.37.15_suppl.1056
Abstract #
1056
Poster Bd #
137
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
First Author: Kelvin K H Bao
Poster
2021 ASCO Annual Meeting
A single-arm phase II trial of palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive breast cancer.
First Author: Oana Cristina Danciu
Poster
2020 ASCO Virtual Scientific Program
Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer.
First Author: Ayca Gucalp
Poster
2019 ASCO Annual Meeting
EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigator’s choice (IC) of endocrine therapy (ET) for ER+/HER2- advanced breast cancer (BC) following CDK4/6 inhibitor (CDK4/6i) therapy.
First Author: Aditya Bardia